RZLT is trading 5% up at $5.14 after recent positive updates on its hyperinsulinism programs. - On June 2, the company reported positive interim data from its Phase 3 upLIFT study for tumor hyperinsulinism. - Rezolute also presented new analyses from its Phase 3 sunRIZE study and other hyperinsulinism data at the ENDO 2026 meeting (June 13-16). - These pipeline advancements, combined with a modestly positive broader market, appear to be supporting today's price action.